Latest Videos

The development of organic reactions and bio-organic structures relevant for surfaces will be discussed.

Richard Luxton, University of the West of England, speaking at Point of Care Diagnostics 2015

Imaging has been at the heart of Medicine for many decades. However, its influence is changing as the need increases not only for diagnosis of disease, but also for quantification of disease extent, identification of suitable candidates for treatment and for testing of both treatment response or assessment of potential side effects for new treatments.

This talk presents the discovery and optimization of potent and selective MPS1 inhibitors based on the 1H-pyrrolo[3,2-c]pyridine scaffold, guided by structure-based design and cellular characterization of MPS1 inhibition.

Present diagnostic procedures and therapeutic strategies solid tumours rely on the detection and targeting of specific marker molecules to classify the tumour and to design an efficient therapy.

The presented work deals with the development of a fragment based strategy for dual-target drug discovery.

Metabolomics has been successfully applied to identify and validate biomarkers for congestive heart failure. Diagnosis and risk stratification of heart failure (HF) is challenging.

There is often a debate about just how useful fragments are for well-established conventional targets such as protein kinases. Fragment screening however can be extremely valuable, providing critical ideas that lead to novelty, demonstrating how to achieve selectivity, helping dissect and make the most of HTS and literature compounds, alongside maximising ligand efficiency.

Targeted mass spectrometry, called MRM or SRM, allows for the rapid quantification of hundreds of proteins in a single assay. This tool is very specific, highly quantitative and requires very little sample (e.g. < 5 uL plasma).

Research/routine and quantitative/qualitative analyses using LC-HR-MS will be presented for drug and peptide determinations in patients’ plasma.